GVK Biosciences (GVK BIO) today announced that it has entered into an agreement with Dr. Kimito Funatsu, University of Tokyo on its GPCR Databases. Dr. Kimito Funatsu, a world-renowned professor, teaches at University of Tokyo’s prestigious Department of Chemical System Engineering.
Various methods are available to ensure the quality of medical translations – but some are more effective than others.
Dutch biotechnology company Amarna Therapeutics B.V. and the Netherlands Organisation for Applied Scientific Research TNO today announced that they have entered into a collaboration agreement to further develop Amarna's viral gene delivery platform SVac.
IDBS has announced that the Immunovirology Division of the French Atomic Energy Agency (Commissariat à l’Ènergie Atomique, CEA) has selected E-WorkBook for biology (BioBook) to capture, collate, analyze and share experimental data across its multi-user immunovirology research projects.
IDBS, a leading provider of innovative data management solutions for research science, announces the formation of a strategic relationship with the Department of Chemistry at the University of Cambridge.
Glycotope Biotechnology, an established CMO equipped with state-of-the-art technologies and more than 25 years of experiences in GMP production of biotherapeutics announces the approval for fill finish of clinical grade material. Since then, the company has successfully completed five fill and finish projects for different customers.
Digital pen and paper technology captures handwritten clinical data electronically, quickly and securely to save time and cost in drug discovery process.
Survey reveals detrimental impact on organisational effectiveness and IT expenditure in healthcare and finance across the UK, France, Germany and the US.
GVK Biosciences (GVK BIO) and CRELUX announced today that they have set-up a highly robust fragment-based drug discovery platform proven to deliver rapidly, viable lead molecules. CRELUX’s high performance structural biology technologies together with GVK BIO’s mature computer-assisted drug design (CADD) tools and other components of its drug discovery and development engine, encompass all steps from challenging targets to novel drug candidates.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.